The invention is directed to physiologically active compounds of the general formula (Ix)
and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS
申请人:Aventis Pharmaceuticals Inc.
公开号:EP1441725A1
公开(公告)日:2004-08-04
US6897208B2
申请人:——
公开号:US6897208B2
公开(公告)日:2005-05-24
US8288425B2
申请人:——
公开号:US8288425B2
公开(公告)日:2012-10-16
[EN] BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS<br/>[FR] BENZIMIDAZOLES ET ANALOGUES ET LEUR UTILISATION COMME INHIBITEURS DE PROTEINES KINASES
申请人:AVENTIS PHARMA INC
公开号:WO2003035065A1
公开(公告)日:2003-05-01
The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.